Programs

View pipeline chart

We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.

 

Theravance Biopharma Respiratory Program

Inhaled Long-Acting Muscarinic Antagonist (LAMA)
TD-4208

We are developing TD-4208, an investigational, once-daily, inhaled nebulized muscarinic antagonist discovered by Theravance, for the treatment of a subset of chronic obstructive pulmonary disease (COPD) patients whom we believe are underserved by current hand held products. We believe that such a medicine could serve as a foundation for several combination nebulized products as well as potential metered dose inhaler (“MDI”) or dry powder inhaler (“DPI”) products.

Form content here please :)